Cisplatin-resistant epithelial ovarian cancers exhibit EMT-like properties including enhanced migratory and invasive activity, while BEZ235, a dual PI3K/mTOR inhibitor, was able to reverse EMT phenotypes, reversing these invasive and migratory capabilities, restoring their chemotherapeutic sensitivity33. This evidence concerns the gene MTOR and ovarian carcinoma.